Rinvoq Criteria Consolidated — Indication‑Specific Starts, Renewals & Prescriber Rules

Cigna updated Rinvoq (JAK inhibitor) coverage criteria effective 2026-03-15, consolidating indication-specific initiation, renewal, formulation limits, and prescriber requirements across dermatology, rheumatology, and gastroenterology indications. Initial approval durations now vary by indication (e.g., 3 months for atopic dermatitis ≥12 years; 6 months for psoriatic arthritis, rheumatoid arthritis, Crohn’s and other rheumatologic indications) with explicit prior‑therapy requirements (including TNFi trial for rheumatologic/Crohn’s indications and specified biologics or systemic agents for dermatology). Renewal approvals allow up to 1 year when patients meet condition‑specific minimum treatment durations and demonstrate objective clinical benefit using listed instruments or symptom improvements (e.g., BSA/pruritus for atopic dermatitis; ASDAS/BASDAI for axial disease; DAPSA/MDA for psoriatic arthritis). Specialist prescriber or consultation requirements are reinforced by indication (dermatology/allergy/immunology for AD, gastroenterology for Crohn’s, rheumatology for arthritis/axial disease).

Summary of revisions in this version

This revision of Cigna's IP0682 clarifies and consolidates coverage criteria for Rinvoq (a JAK inhibitor) across multiple FDA‑approved inflammatory indications, with effective date 2026-03-15. The document specifies formulation limits for initial and continuing use (e.g., approvals distinguish between Rinvoq extended‑release tablets and Rinvoq LQ oral solution for certain indications). It also aligns duration of initial approvals and renewal intervals with indication‑specific requirements (for example, 3‑month initial approval for atopic dermatitis versus 6‑month initial approvals for several rheumatologic and gastrointestinal indications).

The revision organizes objective response criteria and prescriber specialty requirements more explicitly by indication. For inflammatory joint and axial disease indications the policy lists specific objective measures (e.g., ASDAS, BASDAI, HAQ‑S) that can document benefit. For dermatology indications it lists skin‑specific outcomes (e.g., body surface area, erythema, excoriations) and requires specialist involvement (allergist, immunologist, or dermatologist) for initial therapy.

Indication‑specific initiation and duration rules for `Rinvoq`

Evidence of clinical benefit and objective measures required

For continued coverage, the policy requires documented clinical benefit from baseline using either objective disease activity measures or symptom improvement depending on the condition. For axial spondyloarthritis and ankylosing spondylitis, acceptable objective measures include ASDAS, BASDAI, BASFI, BAS‑G, BASMI, HAQ‑S, and serum inflammatory markers (CRP, ESR). For psoriatic arthritis, the policy lists disease activity instruments such as DAPSA, CPDAI, PsA DAS, LEI, SPARCC, MDA, and PsAID‑12 as examples.

For atopic dermatitis, objective responses include estimated body surface area affected, erythema, induration/papulation/edema, excoriations, lichenification, or reduced need for other topical/systemic therapies; symptom improvement examples include reduced pruritus. These structured examples are used to determine whether a patient has experienced a beneficial clinical response for continuation of therapy.

Prescriber specialty and prior therapy specifications

The policy specifies prescriber specialty requirements linked to indications. Initial atopic dermatitis requests must be prescribed by or in consultation with an allergist, immunologist, or dermatologist. Gastroenterology consultation is required for Crohn's disease initiation, and rheumatology oversight is required for axial spondyloarthritis, psoriatic arthritis, and other rheumatologic indications. These specialty requirements are embedded in the initial approval criteria.

Prior therapy requirements are indication‑specific and enumerate acceptable comparators. For dermatology, prior systemic therapies explicitly include biologics (Dupixent, Ebglyss, Nemluvio, Adbry) as well as traditional immunosuppressants (methotrexate, azathioprine, cyclosporine, mycophenolate mofetil). For rheumatologic and Crohn's disease indications, the policy requires a trial of at least one tumor necrosis factor inhibitor (with reference to an Appendix for examples). The policy also notes that conventional synthetic DMARDs do not count toward the TNFi requirement for psoriatic arthritis.

OpenPayer

March 2026 Revision: Rinvoq Criteria Consolidation

Summary of revisions in this version

Initiation and Duration Requirements by Indication

Indication‑specific initiation and duration rules for `Rinvoq`

Documentation of Benefit: Objective Measures and Symptoms

Evidence of clinical benefit and objective measures required

Specialist Prescriber and Prior Therapy Rules

Prescriber specialty and prior therapy specifications

March 2026 Revision: Rinvoq Criteria Consolidation

Summary of revisions in this version

Initiation and Duration Requirements by Indication

Indication‑specific initiation and duration rules for Rinvoq

Documentation of Benefit: Objective Measures and Symptoms

Evidence of clinical benefit and objective measures required

Specialist Prescriber and Prior Therapy Rules

Prescriber specialty and prior therapy specifications

Indication‑specific initiation and duration rules for `Rinvoq`